These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 8703810

  • 1. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia.
    Arya R, Rolan PE, Wootton R, Posner J, Bellingham AJ.
    Br J Haematol; 1996 Jun; 93(4):817-21. PubMed ID: 8703810
    [Abstract] [Full Text] [Related]

  • 2. The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects.
    Rolan PE, Parker JE, Gray SJ, Weatherley BC, Ingram J, Leavens W, Wootton R, Posner J.
    Br J Clin Pharmacol; 1993 Apr; 35(4):419-25. PubMed ID: 8485022
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: a possible therapeutic approach to sickle cell disease.
    Keidan AJ, Sowter MC, Johnson CS, Marwah SS, Stuart J.
    Clin Sci (Lond); 1989 Apr; 76(4):357-62. PubMed ID: 2714049
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.
    Rolan PE, Mercer AJ, Wootton R, Posner J.
    Br J Clin Pharmacol; 1995 Apr; 39(4):375-80. PubMed ID: 7640143
    [Abstract] [Full Text] [Related]

  • 5. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, Silva-Garcia A, Zhou C, Hutchaleelaha A, Patskovska L, Patskovsky Y, Almo SC, Sinha U, Metcalf BW, Archer DR.
    Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
    [Abstract] [Full Text] [Related]

  • 6. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
    Henry ER, Metaferia B, Li Q, Harper J, Best RB, Glass KE, Cellmer T, Dunkelberger EB, Conrey A, Thein SL, Bunn HF, Eaton WA.
    Blood; 2021 Sep 30; 138(13):1172-1181. PubMed ID: 34197597
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of sickle cell anemia with hydroxyurea and erythropoietin.
    Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S, Bunn HF.
    N Engl J Med; 1990 Aug 09; 323(6):366-72. PubMed ID: 1695325
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial.
    Gori A, Trabattoni D, Bandera A, Saresella M, Marchetti G, Gazzola L, Biasin M, Rhodes J, McDade H, Panebianco R, Galli M, Moroni M, Ferrante P, Thomas N, Franzetti F, Bray D, Clerici M.
    Antivir Ther; 2004 Aug 09; 9(4):603-14. PubMed ID: 15456092
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.